Mark Vollenweider, MD
Pulmonary Disease · Orlando, FLNPI 1356331698
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,750 of the $36,851 with a category attached, or 75.3%. Pulmonx Corporation accounts for 76.2% of it on its own, with 21 other manufacturers making up the rest. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $297.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$28K
- Johnson & Johnson$5K
- Intuitive Surgical$2K
- AstraZeneca$311
- GSK$289
- Galvanize Therapeutics, Inc$211
- plus $921 from 16 others
Across 15 payments — averaging $1020.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pulmonx Corporation$15K
What the payments were for
- Consulting fees$27,75075%
- Travel & lodging$4,45412%
- Food & beverage$4,60012%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 28 | $28,095 |
| Johnson & Johnson(2 entities) | 10 | $5,316 |
| Intuitive Surgical | 16 | $1,708 |
| AstraZeneca | 13 | $311 |
| GSK | 13 | $289 |
| Galvanize Therapeutics, Inc | 2 | $211 |
| Sunovion Pharmaceuticals Inc. | 10 | $196 |
| Merck | 6 | $175 |
| Sanofi | 3 | $127 |
| Boehringer Ingelheim | 5 | $91 |
| Veran Medical Technologies, Inc. | 1 | $74 |
| Mallinckrodt Enterprises LLC | 3 | $51 |
| Regeneron Healthcare Solutions, Inc. | 3 | $46 |
| Insmed, Inc. | 2 | $32 |
| Advanced Respiratory, Inc | 2 | $20 |
| Auris Health, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| Electromed, Inc. | 1 | $17 |
| Bayer | 1 | $14 |
| SPR Therapeutics, Inc | 1 | $14 |
| Fisher & Paykel Healthcare Inc | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$28,030
- CHARTIS CATHETER$13,147
- ZEPHYR DELIVERY CATHETER$13,147
- PULMONX CHARTIS TABLET CONSOLE$13,147
- MONARCH$4,900
- Da Vinci Surgical System$950
- ALIYA SYSTEM$136
- ION$135
- BREZTRI$125
- Monarch Platform$123
- NUCALA$122
- RYBREVANT$102
How this compares
$36,851 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Orlando
- Ali JiwaniOrlando$859K
- Junaid MalikOrlando$429K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.